PMID- 31347096
OWN - NLM
STAT- MEDLINE
DCOM- 20200911
LR  - 20220801
IS  - 1179-1934 (Electronic)
IS  - 1172-7047 (Linking)
VI  - 33
IP  - 8
DP  - 2019 Aug
TI  - Immune Globulin Subcutaneous (Human) 20% (Hizentra((R))): A Review in Chronic 
      Inflammatory Demyelinating Polyneuropathy.
PG  - 831-838
LID - 10.1007/s40263-019-00655-x [doi]
AB  - Intravenous immunoglobulin (IVIg) is well-established in the treatment of 
      patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Immune 
      globulin subcutaneous (human) 20% liquid (Hizentra((R)); referred to as IgPro20 
      hereafter) has recently been approved in a number of countries, including the USA 
      and those of the EU, as maintenance therapy in patients with CIDP. In the pivotal 
      phase III PATH trial in adults with CIDP who were first stabilized on IVIg 
      therapy, maintenance therapy with IgPro20 for 24 weeks significantly reduced CIDP 
      relapse or study withdrawal rates versus placebo. Efficacy was sustained 
      during </= 48 weeks of additional treatment with IgPro20 in the open-label PATH 
      extension study. IgPro20 was generally well tolerated, with low rates of systemic 
      adverse events (AEs); the most common AEs were local reactions (e.g. 
      infusion-site erythema, infusion-site swelling). In PATH, more than one-half of 
      IgPro20 recipients preferred this therapy to their previous IVIg therapy. IgPro20 
      offers a convenient alternative to IVIg with a better systemic AEs profile and 
      thus extends the options for maintenance therapy in CIDP.
FAU - Lamb, Yvette N
AU  - Lamb YN
AD  - Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. 
      demail@springer.com.
FAU - Syed, Yahiya Y
AU  - Syed YY
AD  - Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
FAU - Dhillon, Sohita
AU  - Dhillon S
AD  - Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
LA  - eng
SI  - figshare/10.6084/m9.figshare.8940242
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - CNS Drugs
JT  - CNS drugs
JID - 9431220
RN  - 0 (Hizentra)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Humans
MH  - Immunoglobulin G/*administration & dosage
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Injections, Subcutaneous/methods
MH  - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/*drug therapy
EDAT- 2019/07/28 06:00
MHDA- 2020/09/12 06:00
CRDT- 2019/07/27 06:00
PHST- 2019/07/28 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
PHST- 2019/07/27 06:00 [entrez]
AID - 10.1007/s40263-019-00655-x [pii]
AID - 10.1007/s40263-019-00655-x [doi]
PST - ppublish
SO  - CNS Drugs. 2019 Aug;33(8):831-838. doi: 10.1007/s40263-019-00655-x.